

Seat No.: _____

Enrolment No. _____

GUJARAT TECHNOLOGICAL UNIVERSITY
M. Pharm. – SEMESTER – I • EXAMINATION – SUMMER -2018

Subject Code: MRA102T**Date: 05/05/2018****Subject Name: Documentation and Regulatory Writing****Time: 02:30PM TO 05:30PM****Total Marks: 80****Instructions:**

1. Attempt any five questions.
2. Make suitable assumptions wherever necessary.
3. Figures to the right indicate full marks.

- | | | | |
|-------------|-----|--|-----------|
| Q.1 | (a) | Give objectives of Drug master file (DMF). Compare US and European Drug master file preparation. | 06 |
| | (b) | Discuss in detail Certificate of Analysis (CoA) with its purpose and scope | 05 |
| | (c) | Write a note on Product Development Report | 05 |
| Q.2 | (a) | What do mean by BMR. Explain various steps involving to complete BMR. | 06 |
| | (b) | Write a note on Product Development Plan. | 05 |
| | (c) | What do you mean by Batch Reconciliation? Explain its objective and task performed during batch reconciliation. | 05 |
| Q.3 | (a) | What do you mean by CTD? Discuss modules of CTD. | 06 |
| | (b) | What do you mean by eCTD? Give its advantages and disadvantages. | 05 |
| | (c) | Discuss Non eCTD electronic submissions (NeeS) with suitable example. | 05 |
| Q.4 | (a) | Define audits. Enlists types of audits. Explain in brife Audit policy. | 06 |
| | (b) | Write a short note on Company Auditor. | 05 |
| | (c) | Discuss in detail submission process in SUGAM system of CDSCO. | 05 |
| Q.5 | (a) | Discuss in detail about preparation for pre-approval inspections of FDA. | 06 |
| | (b) | Discuss in detail Auditing strategies. | 05 |
| | (c) | Explain in brief Second Party Audits and Third Party Audits. | 05 |
| Q. 6 | (a) | Describe procedure for Inspection of drug distribution channels. | 06 |
| | (b) | Enlist the processing steps for quality systems requirements for national good manufacturing practice inspectorates. Explain purpose and scope for the same. | 05 |
| | (c) | What do you mean by CAPA? Explain purpose of CAPA. | 05 |
| Q.7 | (a) | Explain SUPAC guideline to Industry for Immediate Release Solid Oral Dosage Forms with respect to site change. | 06 |
| | (b) | Define recall. Explain recall procedure for drug product. | 05 |
| | (c) | Describe in detail ISO risk management standard. | 05 |
